Overhaul drug development to refill pipelines, expert says

08/16/2012 | Forbes

Recent failures of highly anticipated drugs show that Big Pharma should "develop a more flexible approach to drug approval and patent exclusivity and change its business model to encourage more scientific collaboration among companies," writes Christopher Bowe, a U.S. health care analyst at Informa Scrip. Working more closely with regulators and payers, accepting sliding patent exclusivity based on comparative effectiveness, and loosening intellectual property protections to encourage more collaboration would help Big Pharma out of the doldrums, Bowe writes.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA